Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 16, 2011

View Archived Issues

Novel lysophospholipid S1P1 receptor agonists disclosed

Study confirms associations between IBD and SNPs in newly identified susceptibility genes

Lundbeck presents new dopamine D2 receptor ligands

Spanish CNIO discloses novel agents for treatment of cancer

Merck & Co. presents new HCV NS5B inhibitors

Gilead claims novel inhibitors of Flaviviridae replication

Primera Bioscience's research project with Hospital for Sick Children achieves next major milestones

New serotonin 5-HT6 receptor antagonists prepared by Cephalon

Advaxis completes pre-IND meeting with FDA for prostate cancer immunotherapy

Vertex synthesizes novel PI3K-gamma inhibitors

Bio-Path completes treatment of first cohort of phase I BP-100-1.01 trial

Teijin and Astellas enter agreement for febuxostat

Mologen provides update on ongoing trials of anticancer candidates

Action Pharma completes phase IIb trial of AP-214

Senesco Technologies begins phase Ib/IIa SNS01-T trial

Hybrid malaria vaccine is safe and immunogenic in malaria-exposed Gabonese infants

Pronova BioPharma submits application for phase I trial of omega-3 fatty acid derivative

MannKind confirms with FDA protocols for two Afrezza trials in diabetes

Impax and GSK report topline results from phase III ASCEND-PD study

New animal model allows identification of therapeutic target for primary open-angle glaucoma

TapImmune and Mayo Clinic to conduct phase I trial of breast cancer vaccine

Chugai obtains exclusive Japanese rights to vemurafenib

Starpharma begins phase II study in prevention of bacterial vaginosis

Enrollment begins in phase II study of RGN-259

Phase III trial of Quad regimen meets primary endpoint

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Cosmo data positive for first new hair-loss approach in decades
BioWorld
Shares of Cosmo Pharmaceuticals NV rose sharply on Dec. 3 following top-line pivotal phase III data showing a statistically significant and clinically meaningful...